Oxford Nanopore sets $700m revenue target for 2030

Health Pharma & Biotech Written by: Ian Lyall 07:41 Wed 19 Aug 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Oxford Nanopore Technologies PLC ( LSE:ONT ) View Price & Profile Oxford Nanopore sets $700m revenue target for 2030 Published: 07:41 19 Aug 2026 BST Oxford Nanopore Technologies PLC (LSE:ONT) , the DNA-sequencing technology company, has set a target of more than $700 million in annual revenue by 2030 as it maps out a path to profitability. The company also expects its margin on adjusted earnings, a measure of underlying profitability that excludes items such as interest, tax and depreciation, to exceed 15% by the same date. Both goals are new. It reaffirmed plans to break even on that earnings measure in 2027 and to generate positive free cash flow from 2028. Over the longer term, the group is aiming to build a business with annual revenue above $1 billion. The targets accompany a new strategy under chief executive Francis Van Parys, built around four priorities spanning biopharma, clinical testing and research. He said investment would be concentrated on a smaller group of high-potential applications where the technology can command clear value. Revenue for the six months to 30 June rose 10.5% to £116.7 million, or 12.3% at constant currency, which strips out currency movements. Growth was strongest in clinical sales, up 35.4%, and biopharma, up 25%, while sales in China fell 15.7%. Gross margin, the share of revenue left after production costs, widened by 4 percentage points to 62.2%. The adjusted loss on the group's preferred earnings measure more than halved to £22.1 million, from £48.3 million a year earlier. The reported loss for the period narrowed to £48 million, from £71.8 million. After the period end, Oxford Nanopore signed a cross-licensing deal with an unnamed global diagnostics firm, worth a $20 million fee this year and $15 million of committed product purchases over the following two years. The company held cash and liquid investments of £234.5 million at the end of June, down from £302.8 million at the end of 2025. Continue reading